All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

Brought to you by

Scientific Education Support logo

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2018-12-07T11:51:27.000Z

Andreas Engert | ASH 2018 | Final phase III results of combined modality treatment in early-stage HL

By Philippa Redondo, Andreas Engert
Featured
Andreas Engert
Dec 7, 2018
Share:

Bookmark this article

60th ASH Annual Meeting & Exposition, December 1-4 2018, San Diego, CA
Andreas Engert
University Hospital of Cologne, Cologne, DE

Interview Topic: Final phase III results of combined modality treatment in early-stage HL

Andreas Engert | ASH 2018 | Final phase III results of combined modality treatment in early-stage HL

More about...
ASH 2018Classical Hodgkin lymphomaHodgkin lymphomaHodgkin lymphoma, not otherwise specified

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 45 days left ...

Related articles

Add bookmark

Carlos Ramos | ASH 2018 | CD30 CAR-T therapy for HL

Carlos Ramos, from Baylor College of Medicine, discusses CD30 CAR T therapy for Hodgkin lymphoma

Dec 21, 2018
Add bookmark

Carlos Ramos | ASH 2018 | CD30 CAR-T therapy for HL

Carlos Ramos, from Baylor College of Medicine, discusses CD30 CAR T therapy for Hodgkin lymphoma

Dec 21, 2018
Add bookmark

Catherine Diefenbach | ASH 2018 | New checkpoint blockade therapy from China with interesting data

Catherine Diefenbach, from NYU Perlmutter Cancer Center, discusses new checkpoint blockade therapy data.

Dec 21, 2018
Add bookmark

Catherine Diefenbach | ASH 2018 | New checkpoint blockade therapy from China with interesting data

Catherine Diefenbach, from NYU Perlmutter Cancer Center, discusses new checkpoint blockade therapy...

Dec 21, 2018

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox